Episode 50

Screening for Circulating Tumour Cells (CTC) with Karin Ried

Download Subscribe
00:00:00
/
01:14:04
RSS Feed Download (67.8 MB) Link with Timestamp

June 2nd, 2020

1 hr 14 mins 4 secs

Link with Timestamp

Download MP3 (67.8 MB)

Your Host
Tags
cancer screening health prostate cancer immune system tumor cells cancer karin ried

About this Episode

Back by popular demand! Associate Professor Dr Karin Ried joins Nathan to discuss the National Institute of Integrative Medicine’s ISET®-CTC test. Ried explains how the test detects CTCs, including how it can distinguish between malignant CTCs and benign circulating epithelial cells, as well as nuances around interpretation of results and the value of monitoring CTCs. Enjoy the highly informative conversation with Dr Ried.

*Highlights *

  1. A very good place to start – what is a CTC? (1:30)
  2. The role the ISET®-CTC test has in integrative oncology (8:00)
  3. Nuances around result interpretation (12:40)
  4. Comparing this test to marker tests (21:20)
  5. Emphasis on the role of the immune system (29:50)
  6. Delivering results to patients (33:20)
  7. Delving into cancer screening (39:00)
  8. Learnings from examining prostate cancer (40:00)
  9. The value of monitoring CTCs (53:30)
  10. Therapeutic considerations (105:00)

Useful links and resources: e.g:
Follow Metagenics Instagram - @metagenics_anz
or Facebook - https://www.facebook.com/metagenics/
If you hold a Metagenics account in Australia or New Zealand join our Facebook Group here - https://www.facebook.com/groups/MetagenicsAU/

Paper – ‘New Screening Test Improves Detection of Prostate Cancer Using Circulating Tumor Cells and Prostate-Specific Markers’ - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192049/